The risk of death with the new ORAL multiple sclerosis drug fingolimod (Gilenya) is too high to use it safely.

This is false...but there are new warnings about serious adverse events with Gilenya.

Now there are reports of serious heart and other problems associated with Gilenya...including 15 deaths.

Tell patients not to’s not known if these deaths were caused by Gilenya. Send worried patients to the pharmacist.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote